Syndax Pharmaceuticals, Inc. (SNDX) Stock Forecast
SNDX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 12 analysts
- Price target
- $37.27 average of analyst targets
- Upside to target
- +188.9% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.51
- 52-week range
- $12.90 – $25.15
SNDX analyst ratings
12 analystsNumber of analysts at each rating.
SNDX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SNDX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.49 | −$0.58 | −$0.38 | −$0.70 | +30.4% | 10 |
| Current fiscal year (2026) | −$1.98 | −$2.25 | −$1.69 | −$3.29 | +40.0% | 10 |
| Next fiscal year (2027) | −$0.84 | −$1.96 | $0.10 | −$1.98 | +57.5% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SNDX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $81.9M | $79.0M | $86.0M | +78.6% | 11 |
| Current fiscal year (2026) | $314.1M | $303.6M | $334.9M | +82.2% | 11 |
| Next fiscal year (2027) | $459.1M | $389.5M | $614.7M | +46.2% | 11 |
SNDX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SNDX revenue: reported and forecast
SNDX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.45 | −$0.47 | −$0.48 | −$0.49 | +23.1% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.70 | −$1.95 | −$1.93 | −$1.95 | −$1.98 | +16.2% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.52 | −$0.65 | −$0.82 | −$0.85 | −$0.84 | +60.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SNDX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SNDX beat in 8 of 12.
What analysts expect from SNDX
12 analysts cover Syndax Pharmaceuticals; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $37.27, 188.9% above the latest close of $12.90. Analysts expect earnings of −$1.98 per share for 2026, +40.0% from a year earlier. For 2027 the average estimate is −$0.84 per share on revenue of $459.1 million. Syndax Pharmaceuticals beat the EPS estimate in 8 of the last 12 quarters.
Related: SNDX income statement, SNDX key metrics, SNDX chart. See the SNDX stock overview for the latest quote and news.
SNDX forecast FAQ
What is Syndax Pharmaceuticals's price target?
The average analyst price target for Syndax Pharmaceuticals is $37.27, 188.9% above the latest close of $12.90.
Is Syndax Pharmaceuticals a buy, hold or sell?
Of 12 analysts covering Syndax Pharmaceuticals, 10 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Syndax Pharmaceuticals's EPS forecast?
Analysts forecast −$1.98 per share for 2026 (range −$2.25 to −$1.69); for 2027 the estimate is −$0.84.
What is Syndax Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $314.1 million, growth of 82.2%; for 2027 it is $459.1 million.
When does Syndax Pharmaceuticals report earnings?
Syndax Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $-0.51.
Does Syndax Pharmaceuticals usually beat earnings estimates?
Syndax Pharmaceuticals reported EPS at or above the analyst estimate in 8 of the last 12 quarters.